Endothelial Nitric Oxide Synthase Gene Expression is Associated with Hypertension in Autosomal Dominant Polycystic Kidney Disease

CardioRenal Medicine

Volumn 4, Issue , 2014, Pages 269-279

  Kocyigit, Ismail ^a   Taheri, Serpil ^a   Sener, Elif Funda ^a   Unal, Aydin ^a   Eroglu, Eray ^a   Öztürk, Fahir ^a   Korkmaz, Kezban ^a   Zararsiz, Gokmen ^a   Imamoglu, Hakan ^a   Sipahioglu, Murat Hayri ^a   Tokgoz, Bulent ^a   Oymak, Oktay ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Endothelial nitric oxide synthase; Hypertension; Polycystic kidney disease

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; CONTROLLED STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

EID: 84919787977     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000369105     Document Type: Article

References (38)

1. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 332-342.
2. Ecder T, Schrier RW: Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001; 12: 194-200.
3. Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA: Progression of autosomal-dominant poly-cystic kidney disease in children. Kidney Int 2001; 59: 1654-1662.
4. Helal I, Reed B, Mettler P, McFann K, Tkachenko O, Yan XD, Schrier RW: Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol 2012; 36: 362-370.
5. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096.
6. Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, et al: Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990; 38: 1177-1180.
7. Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, et al: Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43: 854-860.
8. Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, et al: Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Nephron Clin Pract 2013; 123: 157-164.
9. Kocyigit I, Yilmaz MI, Unal A, Ozturk F, Eroglu E, Yazici C, et al: A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease. Am J Nephrol 2013; 38: 218-225.
10. Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
11. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N: Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349: 837-842.
12. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, et al: Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32: 3-8.
13. Kocyigit I, Kaya MG, Orscelik O, Kaya C, Akpek M, Zengin H, et al: Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 2012; 36: 11-18.
14. Wang D, Iversen J, Strandgaard S: Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-1376.
15. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388.
16. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, et al: Modifier effect of eNOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002; 11: 229-241.
17. Walker D, Consugar M, Slezak J, Rossetti S, Torres VE, Winearls CG, Harris PC: The eNOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am J Kidney Dis 2003; 41: 90-94.
18. Ecder T, McFann KK, Raynolds MV, Schrier RW: No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Am J Nephrol 2003; 23: 466-470.
19. Tazón-Vega B, Vilardell M, Pérez-Oller L, Ars E, Ruiz P, Devuyst O, Lens X, Fernández-Llama P, et al: Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1. Nephrol Dial Transplant 2007; 22: 1567-1577.
20. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, et al; National Kidney Disease Education Program Laboratory Working Group: Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52: 5-18.
21. Kallel A, Sbaï MH, Sediri Y, Abdessalem S, Mourali MS, Feki M, et al: Polymorphisms of the NOS3 gene and risk of myocardial infarction in the Tunisian population. Cytokine 2013; 64: 646-651.
22. Sener EF, Taheri S, Korkmaz K, Zararsiz G, Serhatlioglu F, Unal A, et al: Association of TNF-α -308 G>A and ACE I/D gene polymorphisms in hemodialysis patients with arteriovenous fistula thrombosis. Int Urol Nephrol 2014; 46: 1419-1425.
23. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M: Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 7-13.
24. Schrier RW, Johnson AM, McFann K, Chapman AB: The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1792-1799.
25. Milutinovic J, Rust PF, Fialkow PJ, Agodoa LY, Phillips LA, Rudd TG, Sutherland S: Intrafamilial phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1992; 19: 465-472.
26. Levy M, Duyme M, Serbelloni P, Conte F, Sessa A, Grünfeld JP: Is progression of renal involvement similar in twins with ADPKD? A multicentric European study. Contrib Nephrol 1995; 115: 65-71.
27. Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, Saffen D, et al: Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 2008; 18: 781-791.
28. Cheung VG, Nayak RR, Wang IX, Elwyn S, Cousins SM, Morley M, Spielman RS: Polymorphic cis- and trans-regulation of human gene expression. PLoS Biol 2010; 8:e1000480.
29. Ecder T, Schrier RW: Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009; 5: 221-228.
30. He Q, Fan C, Yu M, Wallar G, Zhang ZF, Wang L, et al: Associations of ACE gene insertion/deletion polymorphism, ACE activity, and ACE mRNA expression with hypertension in a Chinese population. PLoS One 2013; 8:e75870.
31. Oosterga M, Voors AA, de Kam PJ, Schunkert H, Pinto YM, Kingma JH, van Gilst WH: Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997; 95: 2607-2609.
32. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
33. Ji LD, Zhang LN, Shen P, Wang P, Zhang YM, Xing WH, Xu J: Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J Hypertens 2010; 28: 419-428.
34. Pérez-Oller L, Torra R, Badenas C, Milà M, Darnell A: Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34: 273-278.
35. Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, Coles GA, Williams JD: Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52: 607-613.
36. Merta M, Reiterová J, Stekrová J, Rysava R, Rihová Z, Tesar V, et al: Influence of the α-adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic kidney disease. Kidney Blood Press Res 2003; 26: 42-49.
37. Pereira TV, Nunes AC, Rudnicki M, Magistroni R, Albertazzi A, Pereira AC, Krieger JE: Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis. Nephrol Dial Transplant 2006; 21: 3155-3163.
38. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, et al: Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998; 245: 190-193.